UT-HTL
14.4.2021 12:02:13 CEST | Business Wire | Press release
HTL , the worldwide leader in biotechnology solutions using hyaluronic acid (HA) and other biopolymers, and Echelon Biosciences Inc. , a U.S.-based global supplier of biochemical reagents, assays, and services to research and development laboratories, announced today their new distribution and product development partnership. The partnership will enable distribution of high-quality HA and glycosaminoglycan (GAG), and the co-development of novel GAG products.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210414005119/en/
The partnership provides academic research and pharmaceutical development laboratories’ expanded access to Good Manufacturing Practices (GMP)-grade, kit-packaged hyaluronic acid and glycosaminoglycan (GAG) products. By offering premium, clinical grade products to early-stage research investigators, the partnership seeks to bridge the gap between lab-based research, development and commercialization, and accelerate innovation worldwide.
“Innovation is at the heart of HTL’s DNA,” said HTL CEO Yvon Bastard . “This growth opportunity reinforces our mission and vision to apply science for increased bio-compatibility and improved health outcomes around the world.”
“This new partnership offers scientists and researchers the key technologies to develop innovative biopolymer solutions for new medical applications in aesthetics, ophthalmology, rheumatology, tissue engineering and drug delivery,” said Charles Ruban , HTL deputy CEO. “This is the true meaning of HTL’s tagline of ‘Beyond, together.’ HTL’s ambition is not only to grow its lead position in producing and distributing hyaluronic acid worldwide, but also to build tomorrow’s glycosaminoglycan-based solutions.”
“Echelon has been granted the opportunity to expand its market-leading HA assays and extra cellular matrix product line with the supply of HTL ’s hyaluronic acid and other GAG-derived products. HTL is recognized internationally for producing biopolymers of premium quality,” says Bert Israelsen , president of Echelon Biosciences . “Echelon offers our customers access to the latest innovative tools with unparalleled technical support, thereby fully enabling maximized creativity in basic and applied research. With its fermentation and organic synthesis platforms, HTL creates functionality and added value by developing chemically modified biopolymers tailored to specific needs.”
“This new partnership is a milestone in HTL’s expanding footprint in the North American market and with the U.S. medical community,” said Glenn Prestwich, Ph.D ., one of Echelon’s founders and now HTL’s exclusive science and innovation advisor for this market. By entrusting Echelon with the distribution of HTL’s hyaluronic acid and glycosaminoglycan products for research use, HTL aims to significantly increase its support and involvement in biopolymer research in the U.S. and worldwide, but also its research and development capacity.
“This new initiative demonstrates HTL’s commitment to invest in innovation in healthcare,” said Humberto C. Antunes , strategic advisor to HTL and former CEO of Galderma. “In the fields of health and wellness, the biotechnology ecosystem of innovation, incubators, and established and emerging companies are incredibly dynamic in the United States, Mexico and Canada. It means a huge growth potential for HTL products,” added Antunes.
About HTL
HTL is a biotechnology company, leading the way in the design and production of pharmaceutical grade hyaluronic acid and other innovative functional biopolymers for premium medical products. HTL serves the pharmaceutical and medical device industries worldwide, enabling them to transform lives of patients. HTL’s unsurpassed commitment to client partnership has been consistently proven in the marketplace. The company is recognized for supplying the highest quality products and continually investing in driving and supporting market growth. For over 25 years, its cutting-edge research and development has allowed to develop unique value-driven solutions to meet the innovation needs of its clients.
About Echelon Biosciences, Inc.
Based in Salt Lake City, Utah, Echelon Biosciences, was established in 1997 to supply synthetic lipid reagents for research and development. Since then, Echelon has successfully grown in scale and scope to include custom chemistry, peptides, and biological assays with over 700 catalog items in the fields of cell signaling, extracellular matrix, cancer drug discovery, and disease biomarkers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210414005119/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Type One Energy, Tokamak Energy, and AECOM Form the UK Infinity Fusion Consortium to Accelerate Development of a Commercial Fusion Power Plant in the United Kingdom6.5.2026 10:00:00 CEST | Press release
Type One Energy, Tokamak Energy, and AECOM today announced the UK Infinity Fusion Consortium to pursue development of the first private-sector-led fusion power plant project in the United Kingdom. Together, the companies intend to develop a fusion project that is commercially credible, deployable using existing enabling technologies, and capable of attracting private capital — consistent with the long-term goals of the government’s recently announced UK Fusion Strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260506129586/en/ (From left to right) Warrick Matthews, CEO of Tokamak Energy; Chris Mowry, CEO of Type One Energy; and Troy Rudd, Chairman and CEO of AECOM sign the UK Infinity Fusion Consortium during His Majesty King Charles III’s visit to New York City. This announcement comes at a time of increasing U.S.-U.K. bilateral cooperation on fusion. His Majesty King Charles III said during his address to the United
59% of Organizations Made a "Bad AI Hire" in the Past Year, New TestGorilla Research Reveals6.5.2026 10:00:00 CEST | Press release
Study of nearly 2,000 senior hiring leaders finds 53% now prioritize AI fluency over domain expertise, but a critical gap between definitions and measurement is producing confident wrong hires on both sides of the Atlantic TestGorilla, the leading skills-based hiring platform, today released The State of Hiring for AI Fluency, revealing a fundamental shift in talent evaluation: AI fluency has overtaken domain expertise as the top hiring priority. 53% of hiring managers now prefer candidates with strong AI fluency over deep subject matter experts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260506155219/en/ TestGorilla's The State of Hiring for AI Fluency Report Reveals a Transatlantic Divide between US and UK: Study of nearly 2,000 senior hiring leaders finds 53% now prioritize AI fluency over domain expertise, but a critical gap between definitions and measurement is producing confident wrong hires on both sides of the A
Pure Energie Selects Kraken to Manage Wind, Solar and Storage6.5.2026 09:00:00 CEST | Press release
Kraken operating system to manage Pure Energie’s growing portfolio on one intelligent platformPure Energie to benefit from seamless co-ordination across customer load, wind, solar and batteries – maximizing asset value while helping to balance the grid20 sites to onboard in H1 2026, with further expansion planned Pure Energie, a Dutch clean energy company, has selected Kraken – the AI-powered operating system transforming global utilities – to manage and optimize its consumer, wind, solar and battery portfolio across the Netherlands. Kraken brings together grid-scale assets and consumer demand on the same platform, co-ordinating them as a single, intelligent portfolio. This enables Pure Energie to optimize demand and generation in real time – maximizing asset value and helping reduce imbalance costs. The partnership will deliver an energy management system which includes retail balancing, day-ahead curtailment, intraday trading, imbalance optimization, and ancillary market access, alon
Thredd and Currensea Expand Strategic Partnership to Power Next Phase of Growth6.5.2026 09:00:00 CEST | Press release
Four-year renewal builds on long-standing collaboration supporting the payments technology platform behind co-branded reward-earning debit cards and the UK’s top-rated travel spending card Thredd, the AI-first issuer processing platform, today announced the renewal and extension of its longstanding partnership with Currensea, the market-leading payments technology platform. The new agreement extends the relationship for an additional four years, reinforcing a collaboration that has been in place since 2019. Currensea has built a strong reputation among travellers with its multi-bank travel card that links directly to customers’ existing bank accounts, offering competitive FX rates without the need to preload funds. In recent years, Currensea has expanded its offering through co-brand partnerships with leading global travel and hospitality brands, including Hilton Hotels, Marriott Bonvoy and United Airlines, allowing cardholders to earn competitive rewards on their day-to-day debit spen
AMINA Becomes First Bank to Support Canton Coin Trading and Custody6.5.2026 08:30:00 CEST | Press release
Swiss-regulated AMINA provides clients with regulated access to the network that DTCC, Visa, BitGo, and others are building on AMINA Bank AG ("AMINA"), a Swiss Financial Market Supervisory Authority (FINMA)-regulated crypto bank with global reach, today becomes the first bank to support Canton Coin (CC), the native token of Canton Network, offering custody and trading services to its clients. Canton Network is a public, privacy-preserving blockchain built for capital markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260505860056/en/ AMINA Becomes First Bank to Support Canton Coin Trading and Custody Canton has gained significant institutional momentum in recent months, attracting TradFi and DeFi organizations, including the DTCC, Visa, and BitGo, that are building next-generation settlement, tokenisation, custody, and collateral workflows on the network. Canton is also developing an on-chain capital markets ecosystem t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom